Eli Lilly and Company stock price

Eli Lilly and Company latest news:


  • 11/13/2017 08:05:44

    Trump says he's nominating former Eli Lilly executive to head HHS

    President Donald Trump said Monday he is nominating Alex Azar as the next health and human services secretary. Azar, who formerly ran Eli Lilly & Co.'s U.S. operations, would replace Tom Price at the department if confirmed. Price resigned in September amid reports he spent more than $1 million in taxpayer dollars on private plane travel. "He will be a star for better healthcare and lower drug prices!" Trump tweeted. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/09/2017 18:11:33

    BRIEF-New data on Forteo showed reduced risk for new vertebral and clinical fractures in postmenopausal women with ...

    Eli Lilly And Co(LLY). * New data on Forteo® showed reduced risk for new vertebral and clinical fractures in postmenopausal women with severe osteoporosis Source text for Eikon: Further company coverage:

  • 10/27/2017 14:44:45

    UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

    Oct 27 (Reuters) - Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta.

  • 10/24/2017 04:49:31

    Eli Lilly beats profit and sales expectations, as diabetes sales soar 39%

    Eli Lilly & Co. reported Tuesday net income of $555.6 million, or 53 cents a share, down from $778.0 million, or 73 cents a share, in the same period a year ago. Excluding non-recurring items, including asset repairment charges and acquired in-process research and development charges, adjusted earnings per share came to $1.05, above the FactSet consensus of $1.03. Revenue rose 9% to $5.66 billion from $5.19 billion, beating the FactSet consensus of $5.52 billion, as revenue from its diabetes products collectively grew 39%. Among the drug maker's biggest drug sellers, sales of Humalog, Alimta, Cymbalta and Zyprexa beat expectations, while Cialis sales fell short. The company raised its 2017 adjusted EPS outlook to $4.15 to $4.25 from $4.10 from $4.20. The stock, which was still inactive in premarket trade, has gained 2.9% over the past three months, while the SPDR S&P Pharmaceuticals ETF fell 3.9% and the S&P 500 has gained 3.9%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/19/2017 01:32:41

    UPDATE 3-Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

    WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug.

  • 10/10/2017 06:41:10

    Eli Lilly's stock sinks after disappointing results from late-stage trial of cancer treatment

    Shares of Eli Lilly & Co. sank 4.2% in premarket trade Tuesday, after disappointing drug trial results. The company said earlier that a phase 3 trial of its lung cancer treatment Verzenio failed to meet its primary endpoint of overall survival. The company said secondary endpoints of progression-free survival and overall response rate showed evidence of monotherapy activity. Lilly said it would submit the data for presentation at a medical meeting in 2018. "While the outcome is unfortunate for patients with KRAS-mutated, advanced lung cancer, we remain encouraged by the antitumor activity observed with abemaciclib in this form of lung cancer where few clinical advances have been achieved," said Levi Garraway, senior vice president of global development and medical affairs. The stock has run up 18.4% year to date through Monday, while the SPDR S&P Pharmaceuticals ETF has gained 10.8% and the S&P 500 has rallied 13.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/05/2017 14:37:13

    Eli Lilly defeats challenge to Alimta cancer drug patent

    A federal patent review board on Thursday rejected a challenge to a patent covering Eli Lilly and Co's Alimta drug to treat some lung cancers and mesothelioma. The U.S. Patent Trial and Appeal Board said Neptune Generics LLC and other companies failed to show it was more likely than not that 22 claims underlying the Lilly patent could not be patented.

  • 10/05/2017 14:31:47

    BRIEF-U.S. PTO rules in Eli Lilly's favor on Alimta

    Eli Lilly And Co(LLY). * Patent trial and appeal board of U.S. PTO ruled in company's favor regarding patentability of vitamin regimen for Alimta.

  • 10/05/2017 13:06:03

    BRIEF-Eli lilly says Lilly Endowment Inc reports open market sale of 205,000 shares of co's common stock on Oct. 4

    Eli Lilly And Co(LLY). * Eli Lilly And Co(LLY) says Lilly Endowment Inc reports open market sale of 205,000 shares of co's common stock on OCT. 4 at average price of $86.805 per share - SEC filing Source text for Eikon: Further company coverage:

  • 09/28/2017 12:35:49

    UPDATE 1-Eli Lilly wins U.S. approval for breast cancer drug

    Sept 28 (Reuters) - The U.S. Food and Drug Administration said on Thursday it approved an Eli Lilly and Co drug to treat advanced breast cancer that has progressed following prior treatment.

  • 09/14/2017 09:35:18

    CORRECTED-Lilly/Incyte pill beats placebo in mid-stage eczema trial

    Sept 14 (Reuters) - Eli Lilly and Co and Incyte Corp on Thursday said a mid-stage trial of their oral drug baricitinib showed that at the highest dose it worked better than placebo for people with moderate-to-severe atopic dermatitis.

  • 09/07/2017 10:35:44

    Lilly to lay off 8 percent of employees in bid to cut costs

    (Reuters) - Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.

  • 09/07/2017 10:32:00

    UPDATE 3-Lilly to lay off 8 pct of employees in bid to cut costs

    Sept 7 (Reuters) - Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.

  • 09/07/2017 09:22:55

    Lilly to cut 8 percent of jobs in bid to cut costs

    (Reuters) - Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.

  • 09/07/2017 07:31:22

    Eli Lilly to cut 3,500 jobs after part of cost cutting plan

    Eli Lilly & Co. said it will cut about 3,500 jobs, or about 8.3% of its global workforce, as part of a streamlining plan aimed at cutting costs by $500 million a year. The drug giant expects most of the job cuts to come in the U.S. from a voluntary early retirement program, which it expects to be mostly completed by the end of the year. Other workforce reductions are expected to come from streamlining moves, including site closures. Lilly expects to record charges of $1.2 billion, or 80 cents a share, in the third and fourth quarters of 2017. The company plans to use the cost savings to improve its cost structure and reinvest in its business. "The actions we are announcing today will result in a leaner, more nimble global organization and will accelerate progress towards our long-term goals of growing revenue, expanding operating margins and sustaining the flow of life-changing medicines from our pipeline," said Chief Executive David Ricks. The stock, which slipped less than 0.1%, has gained 9.5% year to date through Wednesday, while the SPDR S&P Pharmaceuticals ETF has rallied 8.9% and the S&P 500 has tacked on 10%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 13:23:46

    Incyte shares surge 10% on news that it and Eli Lilly will re-file for arthritis drug approval

    Incyte Corp. shares soared 10.1% in extremely heavy Wednesday trade after news that it and Eli Lilly & Co. plan to reapply for approval of rheumatoid arthritis drug baricitinib by the end of January 2018, with a decision expected mid-year. Eli Lilly shares rose 2.5% in heavy Wednesday trade. The Food and Drug Administration previously failed to approve the drug, asking for more clinical data on dosage and to clarify safety concerns. The two companies said they had discussed the matter with the FDA in late August and that the resubmission package would include new safety and efficacy data. Baricitinib is intended for moderate-to-severe rheumatoid arthritis, can be taken once a day and is expected to generate more than $2 billion in sales a year. Incyte shares have surged 5.7% over the last three months and Eli Lilly shares have surged 2.8%, compared with a 1.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Ellie MaeELLI | Ellington Financial LLCEFC | Ellington Residential Mortgage REITEARN | Embotelladora Andina S.A.AKO.A | Embotelladora Andina S.A.AKO.B | Embraer-Empresa Brasileira de AeronauticaERJ | EMC CorporationEMC | EMCOR GroupEME | Emerge Energy Services LPEMES | Emergent BiosolutionsEBS |